Webinar hosted by Novosanis - A Scalable Liquid Biopsy for HPV-related Cervical Cancer

Global Implications: A Scalable Liquid Biopsy for HPV-related Cervical Cancer

Webinar hosted by Novosanis

Date: Thursday, June 29, 2023 11:00 ET / 17:00 CEST

Compared to invasive clinician-collected cervical scrapes or swabs, non-invasive first-void urine sampling may provide greater coverage of population screening for HPV-related cancers via a patient-preferred and less costly alternative. Invasive clinician-collected cervical scraping is the current gold standard in the US and other countries around the world for HPV-related cancer screening. However, patient access and adherence to HPV screening via clinician-collected samples are limited by factors such as geography, socioeconomic status, patient embarrassment, or patient discomfort. Along with patient barriers to HPV screening, invasive sampling is more costly than self-sampling as demonstrated in an economic evaluation of self-sampling and clinical-collected sampling by Aquarius Population Health.

Join Novosanis next webinar, moderated by Debra Fraser-Howze, Belinda Nedjai Ph.D. (Wolfson Institute of Population Health) and Elisabeth Adams Ph.D. (Aquarius Population Health) where they will present on a non-invasive-first-void urine sample collection as an alternative to clinician collected samples to reduce the cost of care and better support diversity, equity, and inclusion in healthcare.

Key takeaways

1. To discuss how non-invasive sample collection can support better diversity, equity and inclusion in healthcare
2. To gain an appreciation for first void urine as an alternative to clinician-collected samples, including clinical research outcomes and patient preference indicators
3. To understand the impact of self-collected FVU, as compared to clinician-collected samples, at geographic scale including the cost of care